Dalpiciclib plus toremifene for advanced HR+ breast cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs (dalpiciclib and toremifene) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It may be an option if you have not had hormone therapy for advanced disease or if your cancer came back more than a year after prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have breast cancer that is hormone receptor positive and HER2 negative.
- Your cancer has spread or come back and cannot be removed by surgery or cured by radiation.
- You have not had any hormone therapy for advanced cancer, or your cancer got worse more than a year after tamoxifen or more than 6 months after an aromatase inhibitor.
- You are either postmenopausal or willing to receive a shot to suppress ovarian function if premenopausal.
- You are in good general health, with adequate blood counts, liver and kidney function, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy pill (dalpiciclib) combined with hormone therapy for women with advanced breast cancer that is hormone-receptor positive and HER2-negative. It may help shrink tumors or slow their growth when chemotherapy is not an option.
This trial tests a new combination of two drugs (dalpiciclib and an HDAC inhibitor) for people with hormone receptor-positive, HER2-negative advanced breast cancer that has progressed after a CDK4/6 inhibitor. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of two drugs (HRS-8080 and Dalpiciclib) for women with advanced breast cancer that cannot be removed by surgery. It may be an option if you have already tried hormone therapy or are starting advanced treatment for the first time.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.